SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Andre T,Boni C,Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 23432351.
  • 2
    de Gramont A,Boni C,Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. J Clin Oncol. 2005; 23(16S, part I of II): 246S. Abstract 3501.
  • 3
    Brown ML,Nayfield SG,Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst. 1994; 86: 424430.
  • 4
    Norum J,Vonen B,Olsen JA,Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol. 1997; 8: 6570.
  • 5
    Bonistalli L,Bardelli F,Costantini M,Trallori G,d'Albasio G,Messori A. Adjuvant chemotheraphy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis. Cancer J. 1998; 11: 3947.
  • 6
    Koperna T,Semmler D. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. Hepatogastroenterology. 2003; 50: 19031909.
  • 7
    Gold MR,Siegel JE,Russell LB,Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
  • 8
    Gelber RD,Goldhirsch A,Cole BF. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments.International Breast Cancer Study Group. Control Clin Trials. 1993; 14: 485499.
  • 9
    Moertel CG,Fleming TR,Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995; 122: 321326.
  • 10
    Ramsey SD,Andersen MR,Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000; 88: 1294303.
  • 11
    Sullivan PW,Lawrence WF,Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005; 43: 736749.
  • 12
    Shaw JW,Johnson JA,Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005; 43: 203220.
  • 13
    Lin DY,Feuer EJ,Etzioni R,Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997; 53: 419434.
  • 14
    Chaudhary MA,Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med. 1996; 15: 144758.
  • 15
    Sargent DJ,Adjuvant Colon Cancer Endpoints (ACCENT) Group. Endpoints for Colon Adjuvant Clinical Trials (CACT): recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials. J Clin Oncol (Suppl). 2005; 23(16S Part I of II): 249s. Abstract 3512.
  • 16
    Moertel CG,Fleming TR,Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322: 352358.
  • 17
    de Gramont A,Boni C,Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. J Clin Oncol. 2005; 23(16S, Part I of II): 246S. Abstract 3501.
  • 18
    Wolmark N,Wieand S,Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J Clin Oncol (Meeting Abstracts). 2005; 23: LBA3500.
  • 19
    Sargent D,Wieand S,Goldberg R. 3 Year DFS vs. 5 year OS as an endpoint for adjuvant colon cancer studies: data from randomized trials. Available at URL: http://www.fda.gov/cder/drug/cancer_endpoints/sargent/sld001.htm. Accessed on 15-6-2004
  • 20
    Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 17 Regs Public-Use, Nov 2005 Sub (1973–2003 varying). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available from URL: www.seer.cancer.gov Accessed on 10-10-2006.
  • 21
    Hurwitz H,Fehrenbacher L,Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 23352342.
  • 22
    Goldberg RM,Sargent DJ,Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 2330.
  • 23
    Schrag D. The price tag on progress—chemotherapy for colorectal cancer. N Engl J Med. 2004; 351: 317319.
  • 24
    Hirth RA,Chernew ME,Miller E,Fendrick AM,Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000; 20: 332342.
  • 25
    Ubel PA,Hirth RA,Chernew ME,Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003; 163: 16371641.
  • 26
    Eichler H-G,Kong SX,Gerth WC,Mavros P,Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004; 7: 518528.
  • 27
    Matasar MJ,Sundararajan V,Grann VR,Neugut AI. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging. 2004; 21: 113133.
  • 28
    Messori A,Bonistalli L,Costantini M,Trallori G,Tendi E. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. J Clin Gastroenterol. 1996; 23: 269274.
  • 29
    Launois R,Reboul-Marty J,Henry B,Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics. 1996; 10: 504521.
  • 30
    Grunberg SM,Srivastava A,Grunberg KJ,Weeks J. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer. 2002; 10: 624629.
  • 31
    Cook J,Richardson J,Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ. 1994; 3: 157168.